Cough: impact, beliefs, and expectations from a national survey

Negro, Roberto W. Dal; Mazzolini, Massimiliano; Turco, Paola; Zanasi, Alessandro

doi:10.1186/s40248-016-0072-1

Cited by 7 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In comparison with our data, the prevalence of cough in population-based surveys is higher (9% to 33%) than in primary care [ 1 ], most likely due to its self-limiting course. A population-based telephone survey in Italy showed that 23% of subjects would use domestic remedies, 21% would ask their pharmacist and only 33% would consult their doctor [ 61 ]. However, when it comes to consultation, for the majority of people (69.6%-73.7%) the GP is the first address [ 61 , 62 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence, aetiologies and prognosis of the symptom cough in primary care: a systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Background Cough is a relevant reason for encounter in primary care. For evidence-based decision making, general practitioners need setting-specific knowledge about prevalences, pre-test probabilities, and prognosis. Accordingly, we performed a systematic review of symptom-evaluating studies evaluating cough as reason for encounter in primary care. Methods We conducted a search in MEDLINE and EMBASE. Eligibility criteria and methodological quality were assessed independently by two reviewers. We extracted data on prevalence, aetiologies and prognosis, and estimated the variation across studies. If justifiable in terms of heterogeneity, we performed a meta-analysis. Results We identified 21 eligible studies on prevalence, 12 on aetiology, and four on prognosis. Prevalence/incidence estimates were 3.8–4.2%/12.5% (Western primary care) and 10.3–13.8%/6.3–6.5% in Africa, Asia and South America. In Western countries the underlying diagnoses for acute cough or cough of all durations were respiratory tract infections (73–91.9%), influenza (6–15.2%), asthma (3.2–15%), laryngitis/tracheitis (3.6–9%), pneumonia (4.0–4.2%), COPD (0.5–3.3%), heart failure (0.3%), and suspected malignancy (0.2–1.8%). Median time for recovery was 9 to 11 days. Complete recovery was reported by 40.2- 67% of patients after two weeks, and by 79% after four weeks. About 21.1–35% of patients re-consulted; 0–1.3% of acute cough patients were hospitalized, none died. Evidence is missing concerning subacute and chronic cough. Conclusion Prevalences and incidences of cough are high and show regional variation. Acute cough, mainly caused by respiratory tract infections, is usually self-limiting (supporting a “wait-and-see” strategy). We have no setting-specific evidence to support current guideline recommendations concerning subacute or chronic cough in Western primary care. Our study presents epidemiological data under non non-pandemic conditions. It will be interesting to compare these data to future research results of the post-pandemic era.

show abstract

Section: Discussionmentioning

confidence: 99%

“…A population-based telephone survey in Italy showed that 23% of subjects would use domestic remedies, 21% would ask their pharmacist and only 33% would consult their doctor [ 61 ]. However, when it comes to consultation, for the majority of people (69.6%-73.7%) the GP is the first address [ 61 , 62 ].…”

Section: Discussionmentioning

confidence: 99%

Prevalence, aetiologies and prognosis of the symptom cough in primary care: a systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Generally, parents’ concerns increase when their children’s cough lasts for more than a week. Consequently, parents often seek for a medical consultation with a requirement for drug treatment, although most antitussive drugs lack evidence of effectiveness [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of the syrup “KalobaTUSS®” as a treatment for cough in children: a randomized, double blind, placebo-controlled clinical trial

Carnevali¹,

Paglia²,

Pauletto³

et al. 2021

BMC Pediatr

View full text Add to dashboard Cite

Background Acute cough in children often causes discomfort to children and parents, reducing their quality of life. Despite the extensive utilization of over-the-counter remedies for cough, the efficacy of most of these treatments in children has not been confirmed. Methods We conducted a randomized, double blind, placebo-controlled clinical trial of 106 children with acute cough to evaluate the efficacy and safety of KalobaTUSS®, a paediatric cough syrup based on acacia honey and on Malva sylvestris extract, Inula helenium extract, Plantago major extract, and Helichrysum stoechas extract by using a validated 6 points Likert scale. Results Children were orally treated with KalobaTUSS® or placebo for 8 days. Children receiving KalobaTUSS® showed an early and significant reduction in night-time and day-time cough scores measured using a specific scale and a shorter duration of cough than children treated with the placebo. Conclusions KalobaTUSS® is well tolerated and produces positive effects by reducing the severity and shortening the duration of cough in children. Trial registration Clinicaltrials.gov no. NCT04073251. Retrospectively registered.

show abstract

“…Generally, parents' concerns increase when children's cough lasts for more than a week. Consequently, often occurs that parents seek for a medical consult with requirement of drug treatment, though most of antitussive drugs lack of evidence of effectiveness and safety [4].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of the Syrup "KalobaTUSS® " for the Treatment of Cough in Children: a randomized, double blind, placebo-controlled clinical trial

Paglia

Carnevali²,

Pauletto³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Persistent cough in children often causes discomfort to children and parents reducing their quality of life. In spite of the extensive utilization of over the counter remedies against cough, for most of them efficacy in children has not been demonstrated. Methods: We conducted a randomized, double blind, placebo-controlled clinical trial recruiting 106 children with persistent cough to evaluate the efficacy and safety of KalobaTUSS®, a pediatric cough syrup based on acacia honey and on moieties derived from Malva sylvestris extract, Inula helenium, Plantago major extract, Helichrysum stoechas. Results: Children were orally treated with KalobaTUSS® or placebo for eight days. Children receiving KalobaTUSS® showed an early significant reduction in night-time and day-time cough score measured through a specific scale and a shorter duration of cough in comparison to placebo. Conclusions: Results show that KalobaTUSS® is well tolerated and produces positive effects by reducing severity and shortening the duration of cough in children. (Clinicaltrials.gov n. NCT04073251).

show abstract

Cough: impact, beliefs, and expectations from a national survey

Cited by 7 publications

References 25 publications

Prevalence, aetiologies and prognosis of the symptom cough in primary care: a systematic review and meta-analysis

Prevalence, aetiologies and prognosis of the symptom cough in primary care: a systematic review and meta-analysis

Efficacy and safety of the syrup “KalobaTUSS®” as a treatment for cough in children: a randomized, double blind, placebo-controlled clinical trial

Efficacy and Safety of the Syrup "KalobaTUSS® " for the Treatment of Cough in Children: a randomized, double blind, placebo-controlled clinical trial

Contact Info

Product

Resources

About